Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Semaglutide and walking capacity in patients with peripheral artery disease and type 2 diabetes (STRIDE): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Benton CB, Takahashi K, Bose P, Wang F, H-C C, Zheng X, Zhang J, Wang X, Su X, Montalban-Bravo G, Issa GC, Daver N, Jabbour EJ, DiNardo CD, Bueso-Ramos CE, Patel K, Kornblau SM, Konopleva M, Borthakur G, Kadia TM, Cortes JE, Ravandi F, Andreeff M , Garcia-Manero G, Futreal A, Kantarjian H
Furthermore, the trajectory of the weight loss curves suggested that at 48 weeks the plateau of weight was not yet reached and all the participants in the 8 and 12 mg had a weight reduction of 5% or more, which is currently the minimum threshold for efficacy [64]
doi:10.1371/journal.pone.0255482
